Long-term outcomes of AMS Spectra® penile prosthesis implantation and satisfaction rates
The aim of this study was to evaluate the surgical implantation techniques of AMS Spectra malleable penile prosthesis, its intraoperative and postoperative complications, and the rates of patient and partner satisfaction. Forty-six patients on whom AMS Spectra malleable penile prosthesis implantation was performed between 2009 and 2014 were retrospectively examined. Any complications seen intraoperatively and postoperatively were determined. International Index of Erectile Function (IIEF)-5, total IIEF erectile function domain scores were calculated preoperatively. IIEF-5, total IIEF erectile function domain and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) scores were calculated in the postoperative third, sixth and twelfth months. The mean age of the patients was 63.6 ± 7.28 (38-80) years. The mean erectile dysfunction period was 4.29 ± 2.51 years, and the mean follow-up period was 3.19 ± 1.6 years. The mean IIEF-5 score was 5.86 ± 0.92 before surgery, and it was 22.5 ± 0.62 at the end of the follow-up. The mean total IIEF erectile function domain score was 6.02 ± 1.09 before surgery, and it was 26.02 ± 0.21 at the end of the follow-up. The mean EDITS score was 71.06 ± 3.16 at the end of the follow-up. The mean EDITS score of the patients partners was 65.08 ± 4.34 at the end of the follow-up. The overall satisfaction rates were 96.2% for the patients and 84.6% for the partners. As a result of this study, the AMS Spectra penile prosthesis implantation is an effective, reliable and economic method. It can be used in the treatment of erectile dysfunction in selected patient groups offering high patient and partner satisfaction rates.